REST试验:vv-ECCO2R辅助低潮气量通气对急性低氧性呼吸衰竭长期结局的影响
REST试验预设分析评估vv-ECCO2R辅助低潮气量通气对中重度急性低氧性呼吸衰竭患者长期结局的影响。412例入组患者中391例有2年死亡数据,干预组与标准治疗组死亡时间无差异(HR 1.08,95%CI 0.81-1.44;p=0.61)。1年存活者中161例提供问卷,两组呼吸功能、创伤后应激障碍、认知功能及健康相关生活质量均无差异。
要点
- vv-ECCO2R辅助低潮气量通气未改善中重度AHRF患者2年生存时间。
- 1年存活者中两组呼吸功能、PTSD、认知功能及生活质量无差异。
- 该策略不支持以改善长期结局为目的用于中重度AHRF患者。
核心结论
- vv-ECCO2R辅助低潮气量通气不影响中重度AHRF患者的1年死亡率。
- 在提供问卷应答的患者中,该策略对长期呼吸功能、创伤后应激障碍、认知功能障碍或健康相关生活质量无治疗效应。
研究设计与样本
- REST试验的预设分析,为英国全国多中心随机临床试验。
- 比较vv-ECCO2R辅助低潮气量通气(干预)与标准治疗用于中重度AHRF患者。
- 评估2年死亡率,并在1年存活者中用标准化问卷评估呼吸功能、创伤后应激障碍、认知功能及健康相关生活质量。
- REST试验共入组412例患者,其中391例(95%)有2年死亡结局数据。
主要发现
- 干预组与标准治疗组死亡时间无差异(HR 1.08,95%CI 0.81-1.44;log-rank检验p=0.61)。
- 1年时存活并有至少一份问卷应答的患者共161例。
- 两组间呼吸功能、创伤后应激障碍、认知功能障碍及健康相关生活质量均无差异。
临床怎么用
- 中重度AHRF患者不应期望通过vv-ECCO2R辅助低潮气量通气改善长期生存或功能结局。
- 临床决策应基于该策略对长期结局无获益的证据,权衡其用于AHRF治疗的价值。
局限性
- 长期功能结局分析仅基于1年存活者中提供问卷应答的161例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lower tidal volume ventilation, facilitated by veno-venous extracorporeal carbon dioxide removal (vv-ECCO2R), does not improve 90-day mortality in patients with acute hypoxaemic respiratory failure (AHRF). The aim of this analysis was to evaluate the effect of this therapeutic strategy on long-term outcomes. METHODS: This was a prespecified analysis of the REST trial, a UK-wide multicentre randomised clinical trial that compared lower tidal volume ventilation, facilitated by vv-ECCO2R (intervention), with standard care in the treatment of patients with moderate-to-severe AHRF. Mortality to 2 years was assessed, while respiratory function, post-traumatic stress disorder, cognitive function and health-related quality of life were evaluated in survivors at 1 year using standardised questionnaires. RESULTS: Of 412 patients enrolled into the REST trial, 391 (95%) had 2-year mortality outcome data available. There was no difference in the time to death between intervention and standard care (HR 1.08 (0.81, 1.44); log-rank test p=0.61). 161 patients alive at 1 year provided at least one questionnaire response. There was no difference in respiratory function, post-traumatic stress disorder, cognitive dysfunction or health-related quality of life between patients allocated to intervention or standard care. CONCLUSION: Lower-tidal volume ventilation facilitated by vv-ECCO2R does not affect 1-year mortality in patients with moderate-to-severe AHRF. Of the patients who provided questionnaire responses, there was no treatment effect on long-term respiratory function, post-traumatic stress disorder, cognitive dysfunction or health-related quality of life. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT02654327.
引用
- Boyle AJ, McDowell C, Agus A, et al. Acute hypoxaemic respiratory failure after treatment with lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal: long-term outcomes from the REST randomised trial. Thorax. 2022. PMID: 36198573. doi:10.1136/thorax-2022-218874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。